Literature DB >> 20068339

Changing trends in hepatitis C infection over the past 50 years in Japan.

Hobyung Chung1, Taisuke Ueda, Masatoshi Kudo.   

Abstract

In Japan, hepatocellular carcinoma (HCC) is the fourth leading cause of death in males and the fifth in females. Hepatitis C virus (HCV) is a major cause of HCC in Japan, with 70% of cases being HCV related. HCV genotype 1b, the most prevalent subtype in Japan, started to spread in the 1930s among injecting drug users (IDUs) during and after World War II or through medical procedures such as blood transfusion and use of contaminated syringes. The prevalence of HCV infection is much lower in the current younger generation compared with that in the older generation, particularly those aged >55 years (0.1-0.2% vs. > or = 2%). Therefore, the total number of patients with HCV infection is estimated to decrease, even though sporadic HCV transmission is mainly seen among young IDUs. Of note, HCV genotype 2 seems to be spreading among IDUs, but the response to antiviral therapy in these patients seems to be better than that in older patients, irrespective of the genotype. Although the number of patients who die because of HCC has steadily increased over the last 50 years, the incidence of HCC is now decreasing, mainly because of the decreased prevalence of HCV-related HCC. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20068339     DOI: 10.1159/000252782

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  53 in total

Review 1.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

2.  Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.

Authors:  Itaru Ozeki; Jun Akaike; Yoshiyasu Karino; Tomohiro Arakawa; Yasuaki Kuwata; Takumi Ohmura; Takahiro Sato; Naohiro Kamiya; Ichimaro Yamada; Kazuaki Chayama; Hiromitsu Kumada; Joji Toyota
Journal:  J Gastroenterol       Date:  2011-05-10       Impact factor: 7.527

3.  Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.

Authors:  Yi-Ping Li; Santseharay Ramirez; Sanne B Jensen; Robert H Purcell; Judith M Gottwein; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

4.  Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.

Authors:  Goki Suda; Chitomi Hasebe; Masami Abe; Masayuki Kurosaki; Jun Itakura; Namiki Izumi; Yoshihito Uchida; Satoshi Mochida; Hiroaki Haga; Yoshiyuki Ueno; Kazumichi Abe; Atsushi Takahashi; Hiromasa Ohira; Yoko Tsukuda; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Tomoe Kobayashi; Jun Inoue; Katsumi Terasita; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2019-02-18       Impact factor: 7.527

Review 5.  The global epidemiology of hepatocellular carcinoma: present and future.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

Review 6.  Prognostic and clinicopathological significance of MACC1 expression in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Da-Wei Sun; Ying-Yi Zhang; Yue Qi; Gui-Qi Liu; Yu-Guo Chen; Jian Ma; Guo-Yue Lv
Journal:  Int J Clin Exp Med       Date:  2015-04-15

7.  Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases.

Authors:  Luigi Fenoglio; Cristina Serraino; Elisabetta Castagna; Adele Cardellicchio; Fulvio Pomero; Maurizio Grosso; Carlo Senore
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

8.  Projections of primary liver cancer to 2030 in 30 countries worldwide.

Authors:  Patricia C Valery; Mathieu Laversanne; Paul J Clark; Jessica L Petrick; Katherine A McGlynn; Freddie Bray
Journal:  Hepatology       Date:  2017-12-23       Impact factor: 17.425

9.  Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.

Authors:  Joji Toyota; Yoshiyasu Karino; Fumitaka Suzuki; Fusao Ikeda; Akio Ido; Katsuaki Tanaka; Koichi Takaguchi; Atsushi Naganuma; Eiichi Tomita; Kazuaki Chayama; Shigetoshi Fujiyama; Yukiko Inada; Hitoshi Yoshiji; Hideaki Watanabe; Hiroki Ishikawa; Wenhua Hu; Fiona McPhee; Misti Linaberry; Philip D Yin; Eugene Scott Swenson; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2016-08-09       Impact factor: 7.527

10.  Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.

Authors:  Oxana V Makarova-Rusher; Sean F Altekruse; Tim S McNeel; Susanna Ulahannan; Austin G Duffy; Barry I Graubard; Tim F Greten; Katherine A McGlynn
Journal:  Cancer       Date:  2016-03-21       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.